Skip to main content
Premium Trial:

Request an Annual Quote

Allogeneic CAR T-Cell Therapy Assessed in Treatment-Resistant Multiple Myeloma Cases

For a paper in Nature Medicine, investigators at Memorial Sloan Kettering Cancer Center present findings from a Phase I trial dubbed UNIVERSAL aimed at treating relapsed or treatment refractory multiple myeloma with an allogeneic CAR T-cell therapy targeting the B-cell maturation antigen (BCMA) superfamily. "ALLO-715 is a first-in-class, allogeneic, anti-BCMA CAR T-cell therapy engineered to abrogate graft-versus-host disease and minimize CAR T rejection," the team notes, explaining that the current study focused on the safety and tolerability of ALL-715 in 43 relapsed/refractory multiple myeloma cases after a lymphodepletion step. While more than half of the patients experienced cytokine release syndrome and/or infections, neurotoxicities were less common, occurring in 14 percent of patients. When it came to the secondary endpoints, meanwhile, the authors saw response rates approaching 56 percent, including half a dozen patients with a complete response to the allogeneic BCMA-targeting CAR T-cell treatment. Treatment responses appeared to last more than eight months, on average. "The initial results support the feasibility and safety of allogeneic CAR T-cell therapy for myeloma," the authors explain, adding that "[o]ngoing and future studies will also evaluate the importance of the phenotypic characteristics of T cells obtained from healthy donors versus those obtained from relapsed or refractory patients with multiple previous lines of therapy."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.